Pyridyl substituted alkenoic acid derivatives
    1.
    发明授权
    Pyridyl substituted alkenoic acid derivatives 失效
    吡啶基取代的烯酸衍生物

    公开(公告)号:US5248780A

    公开(公告)日:1993-09-28

    申请号:US951760

    申请日:1992-09-25

    IPC分类号: C07D405/04 C07D405/14

    CPC分类号: C07D405/04 C07D405/14

    摘要: The invention concerns novel, pharmaceutically useful 1,3-dioxane alkenoic acid derivatives of the formula I containing a pyridyl moiety at position 4 of the dioxane ring and in which the groups at positions 2, 4 and 5 have cis-relative stereochemistry, X is hydrogen, alkoxy or hydroxy, Y is vinylene, n is 1 or 2, A.sup.1 is alkylene, R.sup.1 is a variety of substituents defined hereinafter, and R.sup.2 is hydroxy, a physiologically acceptable alcohol residue or alkanesulphonamido, and the pharmaceutically acceptable salts thereof. The invention also includes processes for the manufacture and use of the acid derivatives as well as pharmaceutical compositions for therapeutic use in one or more of a variety of diseases such as ischaemic heart disease, cerebrovascular disease, asthmatic disease and/or inflammatory disease.

    摘要翻译: 本发明涉及式I的新型药学上有用的1,3-二烷基链烯酸衍生物,其在二恶烷环的第4位含有吡啶基部分,其中第2,4和5位的基团具有顺式相对立体化学,X是 氢,烷氧基或羟基,Y是亚乙烯基,n是1或2,A1是亚烷基,R1是下文定义的各种取代基,R2是羟基,生理上可接受的醇残基或烷基磺酰氨基,及其药学上可接受的盐。 本发明还包括用于制备和使用酸衍生物的方法以及用于治疗用于一种或多种疾病如缺血性心脏病,脑血管疾病,哮喘病和/或炎性疾病的药物组合物。

    4-pyridyl-1,3-dioxane derivatives
    4.
    发明授权
    4-pyridyl-1,3-dioxane derivatives 失效
    4-吡啶基-1,3-二恶烷衍生物

    公开(公告)号:US5401849A

    公开(公告)日:1995-03-28

    申请号:US78658

    申请日:1993-06-21

    IPC分类号: C07D405/04 C07D405/14

    CPC分类号: C07D405/04 C07D405/14

    摘要: The invention concerns pharmaceutically useful 1,3-dioxane alkenoic acid derivatives of formula VII and formula XI containing a pyridyl moiety at position 4 of the dioxane ring and in which the groups at positions 2, 4 and 5 have cis-relative stereochemistry, wherein X is hydrogen, alkoxy or hydroxy, Y is vinylene, n is 1 or 2, A.sup.1 is alkylene, R.sup.1 is a variety of substituents defined hereinafter, Ra and Rb are independently methyl or ethyl, R.sup.2 is hydroxy, a physiologically acceptable alcohol residue or alkanesulphonamido, and the pharmaceutically acceptable salts thereof.

    摘要翻译: 本发明涉及式VII和式XI的药学上有用的1,3-二恶烷烯酸衍生物,其在二恶烷环的4位含有吡啶基部分,其中2,4和5位的基团具有顺式相对立体化学,其中X 是氢,烷氧基或羟基,Y是亚乙烯基,n是1或2,A1是亚烷基,R1是下文定义的各种取代基,R a和R b独立地是甲基或乙基,R 2是羟基,生理上可接受的醇残基或烷基磺酰胺 ,及其药学上可接受的盐。

    Process for preparing (2R)-methyl-4,4,4-trifluorobutylamine
    7.
    发明授权
    Process for preparing (2R)-methyl-4,4,4-trifluorobutylamine 失效
    制备(2R) - 甲基-4,4,4-三氟丁胺的方法

    公开(公告)号:US5274118A

    公开(公告)日:1993-12-28

    申请号:US803291

    申请日:1991-12-04

    摘要: A process for the preparation of (2R)-methyl-4,4,4-trifluorobutylamine, or an acid addition salt thereof which comprisesa) acylating an optically active amine with 2-methyl-4,4,4-trifluorobutanoic acid or a reactive derivative thereof to afford a butyramide;b) separating (R)-diastereomeric butyramide from (S)-diastereomeric butyramide; andc) converting the (R)-diastereomeric butyramide into the desired (2R)-methyl-4,4,4-trifluorobutylamine, or an acid addition salt thereof. The product may be acylated with a carboxylic acid of formula III ##STR1## wherein U is carboxy, or a reactive derivative thereof to afford (R)-4-[5-(N-[4,4,4-trifluoro-2-methylbutyl]carbamoyl)-1-methylindol-3-yl-methyl]-3-methoxy-N-o-tolylsulphonylbenzamide. The indole is useful as a leukotriene antagonist, for example in the treatment of asthma or allergic rhinitis.

    摘要翻译: 一种制备(2R) - 甲基-4,4,4-三氟丁胺或其酸加成盐的方法,其包括:a)用2-甲基-4,4,4-三氟丁酸或 其反应性衍生物得到丁酰胺; b)从(S) - 非对映异丁基丁酰胺分离(R) - 非对映异构体丁酰胺; 和(c)将(R) - 非对映异构体丁酰胺转化为所需的(2R) - 甲基-4,4,4-三氟丁胺或其酸加成盐。 产物可以用其中U是羧基的式III的羧酸或其活性衍生物酰化,得到(R)-4- [5-(N- [4,4,4-三氟 -2-甲基丁基]氨基甲酰基)-1-甲基吲哚-3-基 - 甲基] -3-甲氧基 - 甲苯磺酰基苯甲酰胺。 吲哚可用作白三烯拮抗剂,例如用于治疗哮喘或过敏性鼻炎。

    1,3-Dioxan-5-yl-hexenoic acids
    8.
    发明授权
    1,3-Dioxan-5-yl-hexenoic acids 失效
    1,3-二恶烷-5-基 - 己烯酸

    公开(公告)号:US4895963A

    公开(公告)日:1990-01-23

    申请号:US217851

    申请日:1988-07-12

    CPC分类号: C07D319/06

    摘要: The invention provides a novel group of 4(Z)-6-([2,4,5-cis]-2-alkyl-4-o-hydroxyphenyl-1,3-dioxan-5-yl)hexenoic acids of formula I wherein R is branched alkyl or 3-5 carbon atoms and one of X and Y is hydrogen or fluoro and the other is hydrogen, and their pharmaceutically acceptable salts; together with their pharmaceutical compositions for use in treating a variety of disease conditions. Also provided are methods for the manufacture of the novel compounds. A representative compound is that in which R is t-butyl and X and Y are both hydrogen.

    1,3-dioxan-5-yl-hexenoic acids
    9.
    发明授权
    1,3-dioxan-5-yl-hexenoic acids 失效
    1,3-二恶烷-5-基 - 己烯酸

    公开(公告)号:US4772625A

    公开(公告)日:1988-09-20

    申请号:US861330

    申请日:1986-05-09

    CPC分类号: C07D319/06

    摘要: The invention provides a novel group of 4(Z)-6-([2,4,5-cis]-2-alkyl-4-o-hydroxyphenyl-1,3-dioxan-5-yl)hexenoic acids of formula I wherein R is branched alkyl of 3-5 carbon atoms and one of X and Y is hydrogen or fluoro and the other is hydrogen, and their pharmaceutically acceptable salts; together with their pharmaceutical compositions for use in treating a variety of disease conditions. Also provided are methods for the manufacture of the novel compounds. A representative compound is that in which R is t-butyl ans X and Y are both hydrogen.

    摘要翻译: 本发明提供了式I的4(Z)-6 - ([2,4,5-顺式] -2-烷基-4-邻羟基苯基-1,3-二恶烷-5-基)己烯酸的新一组 其中R是3-5个碳原子的支链烷基,X和Y之一是氢或氟,另一个是氢,及其药学上可接受的盐; 以及用于治疗各种疾病状况的药物组合物。 还提供了用于制备新型化合物的方法。 代表性化合物是其中R是叔丁基,X和Y都是氢的化合物。